© Reuters.
In a notable turnaround, Krystal Biotech (NASDAQ: NASDAQ:) has reported a significant recovery in its Q3 2023 net income, registering $80.7 million, a stark contrast to the $29.9 million loss it suffered in Q3 2022. This improvement was largely driven by a $100 million gain from the sale of a rare pediatric disease Priority Review Voucher.
The company’s net product revenue for Q3 2023 stood at $8.6 million, generated primarily from sales of VYJUVEK, while the cost of goods sold amounted to $223 thousand. The balance sheet for the period disclosed $598.6 million in cash and investments.
On the expenditure front, R&D expenses have seen a reduction to $10.6 million from $11.5 million in Q3 2022. However, selling and administrative expenses have risen to $23.7 million from $19.9 million over the same period.
In terms of product development, Krystal Biotech made progress in its Phase 1 trials of KB407 for Cystic Fibrosis and KB707 for solid tumors and received clearance for KB408 for Alpha-1 Antitrypsin Deficiency. Looking ahead, the company plans to initiate the Phase 2 cohort of its KB105-02 (JADE-1) trial for TGM1-ARCI and file an IND application for KB104 to treat Netherton Syndrome.
The company also reported its first sales to patients who began treatment in August 2023. More detailed information can be found in the complete 8-K earnings release.
InvestingPro Insights
Drawing from InvestingPro data and tips, it’s clear that Krystal Biotech’s financial landscape is a mixed bag. On one hand, the company holds more cash than debt on its balance sheet, with liquid assets exceeding short-term obligations, which is a strong position to be in. However, the lack of profitability over the last twelve months and the declining trend in earnings per share suggest some financial instability.
InvestingPro data shows a market capitalization of $3420M USD and a negative P/E ratio of -22.58. The company’s return on assets for the last twelve months as of Q2 2023 stands at -21.85%, indicating that the company is not generating a significant profit from its assets.
Despite these challenges, the company has seen a large price uptick over the last six months, with a 6-month price total return of 45.0% and a 1-year price total return of 66.85%.
These insights highlight the importance of a comprehensive understanding of a company’s financial health. For further in-depth analysis and more InvestingPro Tips, consider exploring InvestingPro’s additional resources.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here